What Bi Preterax Treats: Main Uses and Benefits

This medication is relevant for easing essential hypertension (high blood pressure) and is generally applicable in clinical settings that involve certain distressing symptoms. The medicine is applied across domains where additional symptomatic support is needed to help address symptoms related to heightened physiological activity.

The general applications include management of essential hypertension and is considered relevant for conditions characterized by episodic or fluctuating symptom patterns. When symptoms escalate temporarily, Bi Preterax is often used when supportive relief is needed during phases of increased distress or discomfort.

“The medication supports patients during difficult episodes by easing distress and helping address symptoms that create noticeable physiological strain.”

This provides support that contributes to easing the overall symptom load and may assist with managing groups of symptoms that interfere with daily functioning.

---

Quick Fact: Supports Symptom Management for Physiological Strain

---

Regulatory References

1. Irish regulatory Summary of Product Characteristics (SPC)

Who Can and Cannot Use Bi Preterax — Official Regulatory Information

The eligibility for Bi Preterax (a fixed-dose combination of perindopril, an ACE inhibitor, and indapamide, a sulfonamide diuretic) is strictly defined by government regulatory documents based on patient health status and demographics.

Populations for Whom Use is Prohibited (Contraindicated)

• Hypersensitivity: Patients allergic to perindopril, indapamide, any other ACE inhibitor, or any sulfonamide-derived drug.
• Angioedema: Individuals with a history of angioedema (severe swelling of the face, tongue, or throat) related to prior ACE inhibitor use, or hereditary/idiopathic angioedema.
• Reproductive Status: Women in the second or third trimesters of pregnancy, or who are breastfeeding.
• Organ/Electrolyte Status: Patients with severe renal impairment (creatinine clearance < 30 ml/min), severe hepatic impairment or hepatic encephalopathy, hypokalaemia (low blood potassium), or untreated decompensated heart failure.
• Concomitant Use: Contraindicated with aliskiren in patients who have diabetes or renal impairment ( GFR < 60 ml/min/1.73 m^2), and with sacubitril/valsartan (a 36-hour washout period is required).

Other Eligibility Rules

• Age: Children and adolescents should not use this medicine, as safety and efficacy have not been established in this population.
• Pregnancy: Use is not recommended during the first trimester of pregnancy.

The official regulatory profile for Bi Preterax (Perindopril/Indapamide) is structured by several classifications of interaction risk as documented by government health authorities.

Interaction Type	Classification	Interacting Substances/Conditions
Contraindicated	Prohibited Co-Administration	Sacubitril/Valsartan, Extracorporeal treatments, Aliskiren (in patients with diabetes or renal impairment), Non-antiarrhythmic agents causing Torsades de Pointes.
Not Recommended	High Risk of Adverse Outcome	Lithium (increased serum concentration), Potassium-sparing diuretics, Potassium supplements, Potassium-containing salt substitutes.

The combination with Sacubitril/Valsartan is strictly prohibited, and a mandatory 36-hour separation window is required when switching between these treatments. The co-administration of Lithium is not recommended because the components officially reduce its renal clearance, increasing the risk of toxicity. The addition of potassium-sparing diuretics or supplements is similarly discouraged due to the documented potential for hyperkalaemia. Combinations requiring special caution include Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which may reduce the antihypertensive effect and impair kidney function, and mTOR inhibitors (e.g., Everolimus), which carry an increased risk of angioedema. A strict salt-restricted diet is also noted in regulatory documents as a condition that may increase the risk of severe hypotension at treatment initiation. In patients with hepatic impairment, the Indapamide component is documented to carry a risk of precipitating hepatic encephalopathy.

Bi Preterax is a fixed-dose combination of perindopril and indapamide, which modulate physiological systems through distinct mechanisms.

---

Perindopril is a prodrug hydrolyzed to its active metabolite, perindoprilat, which functions as a competitive inhibitor of the somatic angiotensin-converting enzyme (ACE) located primarily in the vascular endothelium. This enzymatic inhibition prevents the conversion of angiotensin I to the potent vasoconstrictor, angiotensin II (Ang II). Reduced Ang II concentration leads to diminished stimulation of the Angiotensin II Type 1 (AT1) receptor on vascular smooth muscle, thereby decreasing systemic vasoconstriction. Furthermore, ACE inhibition reduces the degradation of bradykinin, a vasodilator peptide, increasing its local concentration and contributing to vessel relaxation. The resulting downstream cascade decreases total peripheral vascular resistance and modulates renal hemodynamics.

---

Indapamide is a sulfonamide, thiazide-like agent that acts selectively on the renal distal convoluted tubule. It functions as an inhibitor of the apical membrane Na^+/ Cl^- cotransporter ( NCC). Inhibition of NCC reduces the reabsorption of sodium and chloride ions from the tubular lumen. This intracellular consequence results in increased luminal sodium and water load, leading to a mild increase in water and electrolyte excretion. At the system level, this process decreases circulating plasma volume and contributes to reduced peripheral vascular resistance via extra-renal mechanisms, including direct action on vascular smooth muscle.

---

The combined actions of both compounds produce an additive modulation on both the circulating volume and systemic vascular tone.

How to Use Bi Preterax

This section describes the general principles of administering the fixed-dose combination Bi Preterax (Perindopril/Indapamide) for essential hypertension. The administration instructions are designed to support consistent adherence and drug absorption.

---

Administration Protocol

Feature	Usage Principle
Administration Route	The medicine is intended for oral use only.
Dosing Frequency	The tablet is administered as a single dose once daily.
Dose Level	Standard adult dosing is one tablet per day, available in specific fixed strengths such as Perindopril 5 mg / Indapamide 1.25 mg or Perindopril 10 mg / Indapamide 2.5 mg.
Meal Relationship	The tablet is taken before a meal, typically before breakfast, to maintain consistent bioavailability.
Duration of Use	This medicine is intended for the long-term management of the underlying condition.

---

Procedural Administration Instructions

The film-coated tablet must be swallowed whole with a glass of water, and it should not be split, crushed, or chewed. If a dose is missed, the standard approach is to skip the missed dose and resume the fixed, once-daily schedule with the next dose at the regular time the following morning; double dosing to compensate for a missed dose is not recommended. Furthermore, use in children and adolescents under 18 years is generally not recommended due to insufficient data on efficacy and safety in this population.

Research Evidence / Overview of Studies for Bi Preterax

Evidence for Use in Essential Hypertension

Research has evaluated the fixed-dose combination of perindopril and indapamide (Bi Preterax) for the management of essential hypertension (high blood pressure). Most of the initial evidence comes from Randomized Controlled Trials (RCTs), where researchers studied how this combination was studied against a placebo or other single-pill blood pressure medications. These studies primarily focused on measuring changes in both systolic and diastolic blood pressure (BP) over short- to intermediate-term periods. Trial data describe patterns related to the rates of participants achieving predefined target BP goals established by clinical standards.

Research in High-Risk Cardiovascular Populations

Some of the evidence for this combination comes from large-scale, long-term RCTs that was studied for people with essential hypertension who faced a higher risk for cardiovascular events. These include individuals with Type 2 Diabetes Mellitus (T2DM) or a history of a prior Stroke/Transient Ischemic Attack (TIA). In these studies, researchers monitored major health outcomes, such as Major Vascular Events and all-cause death rates.

In populations with T2DM, studies also explored renal outcomes, examining markers related to kidney function, such as changes in the levels of protein in the urine (albuminuria). Long-term trial reports data describe patterns related to the frequency of Major Vascular Events across the groups that was observed in the study over follow-up periods of several years.

What is Still Uncertain in the Research Landscape

Research provides context but not individual predictions. While evidence exists from major RCTs in high-risk groups, research highlights that comparative evidence is lacking for direct, randomized comparisons against the full range of other currently available combination therapies. Limited information is available for long-term outcomes for the general, low-risk hypertensive population. The results apply only to the populations studied, meaning the research does not determine whether an individual will respond similarly outside of the specific conditions under which the studies were conducted.

Key Studies & References

1. WHO Model List of Essential Medicines (Relevant Antihypertensives and Combination Products)

Common questions about Bi Preterax (FAQ)

---

Q: Can I drink alcohol while taking Bi Preterax?

Regulatory documents indicate that alcohol can increase the blood pressure-lowering effect of the medicine. This may result in symptoms such as dizziness or fainting, particularly when changing position. Patients should consult with a healthcare provider regarding the use of alcohol to understand the potential risks based on their personal health status.

---

Q: Can I take an over-the-counter pain reliever like ibuprofen with this medicine?

Official product information warns that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen, may reduce the antihypertensive effect of Bi Preterax. Combining these medicines can also impair kidney function, particularly in individuals who are elderly or dehydrated. Combining these medicines requires caution and is typically done under the supervision of a healthcare professional.

---

Q: Does Bi Preterax need to be taken with food, or on an empty stomach?

The official administration protocol specifies that the film-coated tablet must be taken before a meal to ensure consistent absorption of the active ingredients. The recommended method of administration is a single daily dose, typically before breakfast.

---

Q: What's the difference between Bi Preterax and Coversyl Plus?

Bi Preterax and Coversyl Plus are simply different brand names used in various global regions for the exact same medicine. They share the same fixed-dose combination containing the active ingredients perindopril and indapamide.

---

Q: Are there different strengths of Bi Preterax available?

The medicine is available in specific fixed-dose strengths, such as the combination of Perindopril 5 mg with Indapamide 1.25 mg, or Perindopril 10 mg with Indapamide 2.5 mg. Dosage strength is determined by a healthcare provider.

---

Q: What should I do if I experience a severe side effect like swelling of the face (angioedema)?

Angioedema (swelling of the face, lips, tongue, or throat) is documented as a serious and very rare adverse reaction. Official information states that these symptoms require the medicine to be stopped immediately, and urgent medical attention should be sought.

How to Store and Dispose of Bi-Preterax

Official regulatory guidelines mandate specific conditions for storing and disposing of Bi-Preterax tablets to maintain product stability and safety.

Storage Requirements

The medicine must be stored at a temperature not exceeding 30 C. To protect the active ingredients, the tablets must be kept in the original pack to shield them from moisture and light. Furthermore, the product must not be used after the expiry date printed on the carton. For child safety, the tablets must always be kept out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Bi-Preterax tablets must not be disposed of via wastewater or household waste. The proper procedure requires that the medicine be disposed of according to local regulations for pharmaceutical waste, which typically involves returning the product to a pharmacist or designated collection point.